

In the Claims:

Please cancel claim 14 without prejudice.

Please amend the claims as follows:

1. (Currently Amended) An immunogen that induces a CTL-response, said immunogen comprising a one or more peptides ~~peptide segment of at least 8 but not more than 14 amino acid units in length which segment comprises each containing a sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 1, 2, 3, 4 and 5 or a sequence differing from said sequence by not more than 1 amino acid residue~~ and wherein said immunogen is not hsp65 protein.

2. (Currently Amended) The immunogen of claim 1 wherein at least one said peptide segment has an contains the amino acid sequence ~~selected from the group consisting of SEQ ID NO: 1, 2, 3, 4 and 5.~~

3. (Currently Amended) The immunogen of claim 1 or 2 wherein said immunogen segment comprises at least 5 copies of one or more of said peptides.

4. (Original) The immunogen of claim 1 or 2 wherein said immunogen is a polypeptide.

5. (Withdrawn) The immunogen of claim 1 wherein said difference of one amino acid residue is the result of a substitution of one hydrophobic amino acid unit by another hydrophobic amino acid.

6. (Withdrawn) The immunogen of claim 1 wherein said difference of one amino acid residue is the result of a substitution of one polar amino acid unit by another polar amino acid.

7. (Withdrawn) The immunogen of claim 1 wherein said difference of one amino acid residue is the result of a substitution of one acidic amino acid unit by another acidic amino acid.

8. (Withdrawn) The immunogen of claim 1 wherein said difference of one amino acid residue is the result of a substitution of one basic amino acid unit by another basic amino acid.

9. (Withdrawn) A polynucleotide comprising a polynucleotide sequence encoding a polypeptide according to claims 4.

10. (Withdrawn) The polynucleotide of claim 9 wherein said polynucleotide is DNA.

11. (Withdrawn) The polynucleotide of claim 9 wherein said polynucleotide is RNA.

12. (Withdrawn) A vector comprising a polynucleotide of claim 9.

13. (Withdrawn) A recombinant mammalian cell comprising the vector of claim 12 and expressing said polynucleotide.

14. (Canceled) ~~A vaccine composition comprising an immunologically active amount of the immunogen of claim 1, 2, 3, 4, 5, 6, 7 or 8 wherein said immunogen is suspended in a pharmaceutically acceptable carrier.~~

15. (Withdrawn) An antibody specific for an immunogen of claim 1, 2, 3, 4, 5, 6, 7 or 8.

16. (Withdrawn) A process for inducing a cytotoxic T lymphocyte (CTL) *in vitro* that is specific for a tuberculosis infected cell expressing HLA-A2 comprising contacting

a precursor CTL with an immunogen of claim 1 under conditions that generate a CTL response to such an infected cell.

17. (Withdrawn) A process for inducing a cytotoxic T lymphocyte (CTL) *in vitro* that is specific for a tuberculosis infected cell expressing HLA-A2 comprising contacting a precursor CTL with an immunogen of claim 2 under conditions that generate a CTL response to such an infected cell.

18. (Withdrawn) A process for inducing a CTL response *in vitro* that is specific for a tuberculosis infected cell expressing HLA-A2, said process comprising contacting a precursor CTL with a mammalian cell of claim 13.

19. (Withdrawn) A process for treating a subject with tuberculosis characterized by tuberculosis infected cells expressing HLA-A2, said process comprising administering CTLs induced by the processes of claims 16, 17 or 18 in an amount sufficient to destroy the infected cells through direct lysis or to effect the destruction of the infected cells indirectly through the elaboration of cytokines.

20. (Withdrawn) The process of claim 18 wherein said infected cells are macrophages.

21. (Withdrawn) A process for treating a tuberculosis-afflicted subject characterized by cells expressing any class I MHC molecule and a gene coding for an epitopic peptide sequence of SEQ ID NO: 1, 2, 3, 4 or 5, whereby the CTLs of claim 19 are administered in an amount sufficient to destroy the infected cells through direct lysis or to effect the destruction of the infected cells indirectly through the elaboration of cytokines.

22. (Withdrawn) The process for claim 21 wherein said infected cells are macrophages.

23. (Withdrawn) A process for inducing a CTL response in a subject, said process comprising administering at least one immunogen of claim 1, 2, 3, 4, 5, 6, 7 or 8, including combinations thereof, to an HLA-A2 positive subject and in an amount sufficient to induce a CTL response to tuberculosis-infected cells expressing HLA-A2.

24. (Currently Amended) An isolated peptide ~~of at least 8 but not more than 14 amino acid residues units in length and having~~ comprising the amino acid sequence of SEQ ID NO: 1 or a sequence differing by no more than one amino acid residue from a ~~sequence selected from the group consisting of the sequence of SEQ ID NO: 1, 4, 2, 3, 4 and 5.~~

25. (Currently Amended) The isolated peptide of claim 24 wherein said ~~oligopeptide has an amino acid sequence selected from the group consisting~~ amino acid sequence is the sequence of SEQ ID NO: 1, 4, 2, 3, 4 and 5.

26. (Withdrawn) The isolated peptide of claim 24 or 25 wherein said difference of one amino acid residue is the result of a substitution of one hydrophobic amino acid unit by another hydrophobic amino acid.

27. (Withdrawn) The isolated peptide of claim 24 or 25 wherein said difference of one amino acid residue is the result of a substitution of one polar amino acid unit by another polar amino acid.

28. (Withdrawn) The isolated peptide of claim 24 or 25 wherein said difference of one amino acid residue is the result of a substitution of one acidic amino acid unit by another acidic amino acid.

29. (Withdrawn) The isolated peptide of claim 24 or 25 wherein said difference of one amino acid residue is the result of a substitution of one basic amino acid unit by another basic amino acid.

30. (Currently Amended) A composition comprising one or more of the isolated peptides of claim 24 or 25 ~~suspended~~ in a pharmacologically acceptable carrier.

31. (Withdrawn) A process for treating a patient afflicted with tuberculosis characterized by tuberculosis infected cells expressing HLA-A2, comprising administering to said patient an effective amount of the antibody of claim 15 in a pharmaceutically acceptable carrier.

32. (Withdrawn) A process for protecting a patient against infection with tuberculosis characterized by tuberculosis infected cells expressing HLA-A2, comprising administering to a patient at risk of such infection an effective amount of the antibody of claim 15 in a pharmaceutically acceptable carrier.

Please add the following new claims:

33. (New) A molecule that induces a CTL-response, said molecule comprising one or more peptides each comprising the amino acid sequence of SEQ ID NO: 1 or a sequence differing from said sequence by not more than 1 amino acid residue and wherein said molecule is not hsp65 protein.

34. (New) The molecule of claim 33 wherein said peptide has the amino acid sequence of SEQ ID NO: 1.

35. (New) The molecule of claim 33 or 34 wherein said molecule comprises at least 5 copies of one or more of said peptides.

36. (New) A molecule that induces a CTL-response, said molecule comprising one or more peptides each containing the amino acid sequence of SEQ ID NO: 5 or a

sequence differing from said sequence by not more than 1 amino acid residue and wherein said molecule is not hsp65 protein.

37. (New) The molecule of claim 36 wherein said peptide has the amino acid sequence of SEQ ID NO: 5.

38. (New) The molecule of claim 36 or 37 wherein said molecule comprises at least 5 copies of one or more of said peptides.

39. (New) An isolated peptide having the amino acid sequence of SEQ ID NO: 5 or a sequence differing by no more than one amino acid residue from the sequence of SEQ ID NO: 5.

40. (New) The isolated peptide of claim 39 wherein said amino acid sequence is the sequence of SEQ ID NO: 5.

41. (New) A molecule that induces a CTL-response, said molecule comprising a plurality of peptides each containing the amino acid sequence of SEQ ID NO: 1 or 5 or a sequence differing from said sequence by not more than 1 amino acid residue and wherein said molecule is not hsp65 protein.

42. (New) The molecule of claim 41 wherein at least one said peptide comprises the amino acid sequence of SEQ ID NO: 1 and at least one said peptide comprises the amino acid sequence of SEQ ID NO: 5.